We serve Chemical Name:3-(1,3-dihydro-isoindol-2-yl)-benzoic acid CAS:130373-81-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(1,3-dihydro-isoindol-2-yl)-benzoic acid
CAS.NO:130373-81-8
Synonyms:3-Isoindolin-2-yl-benzoesaeure;3-(1,3-dihydroisoindol-2-yl)benzoic acid;3-isoindolin-2-yl-benzoic acid;3-(1,3-DIHYDRO-2H-ISOINDOL-2-YL)BENZOIC ACID
Molecular Formula:C15H13NO2
Molecular Weight:239.26900
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:467.2ºC at 760 mmHg
Density:1.284g/cm3
Index of Refraction:1.659
PSA:40.54000
Exact Mass:239.09500
LogP:2.97000
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Isoindolin-2-yl-benzoesaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(1,3-DIHYDRO-2H-ISOINDOL-2-YL)BENZOIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Isoindolin-2-yl-benzoesaeure Use and application,3-Isoindolin-2-yl-benzoesaeure technical grade,usp/ep/jp grade.
Related News: Orchard’s decision last year to put OTL-101 on the back burner left patients with no way to access a seemingly effective therapy for a condition that can kill children before they reach the age of one. Sepedonin-dimethylether (A) manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit tert-butyl 4-(((N-(2-acetoxyphenyl)-2-chlorophenyl)sulfonamido)methyl)piperidine-1-carboxylate suppliers Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms including pain, rashes, fatigue, swelling in joints and fevers. RNA (hepatitis d virus strain Egyptian hepatitis d antigen genefragment) vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit tert-butyl 4-(((N-(2-acetoxyphenyl)-2-chlorophenyl)sulfonamido)methyl)piperidine-1-carboxylate suppliers Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms including pain, rashes, fatigue, swelling in joints and fevers. RNA (hepatitis d virus strain Egyptian hepatitis d antigen genefragment) vendor & factory.
